| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d32a49211015b18ecef5a3a5195bf06e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2007-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66abb067d82d9b0846c609ea21227eac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b41dee9fc2d933d3a3d92bdb1e2c0ee1 |
| publicationDate |
2009-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-101460144-A |
| titleOfInvention |
AchE-NMDA combination wafer |
| abstract |
The invention relates to wafer-like pharmaceutical products based on hydrophilic polymers, which rapidly disintegrate upon contact with humidity and which are used to treat dementia-related illnesses, wherein the presentation contains an active agent combination of at least two active agents suitable for the treatment of dementia (antidementia agents). Preferably, the antidementia agents should be chosen from the group comprising acetyl cholinesterase inhibitors (AChE inhibitors) and NMDA antagonists (n-methyl-D-asparaginic acid antagonists). The invention further relates to the use of such an active agent combination for the production of an orally administrable pharmaceutical product for the treatment of dementia-related illnesses such as Alzheimer's disease, as well as to a procedure for the symptomatic treatment of Alzheimer's disease by means of the oral administration of one of the above pharmaceutical products. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108926549-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109498643-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105806818-A |
| priorityDate |
2006-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |